Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis

Clinical trial NCT04148898 · UNKNOWN

Trial details

NCT number: NCT04148898
Sponsor: Second Affiliated Hospital of Nanchang University
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Leptomeningeal Metastasis Non-small Cell Lung Cancer EGFR Activating Mutation

Start date: 2019-11-01
Primary completion: 2021-03-01
Enrollment: 80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.